Carlo Russo
Chief Medical Officer & Head of Development Genenta Science
Seminars
Wednesday 18th February 2026
Reprogramming Tumor Microenvironment of Wild Type Glioblastoma by Cell Therapy Based on Interferon-Alpha Transduced Autologous TIE-2+ Macrophages: A Phase 1 Study in Newly Diagnosed GBM Patients
9:30 am
- Discussing the development of a novel cell therapy approach that uses modified macrophages to manipulate the tumor microenvironment in glioblastoma
- Highlighting the translation of a wild-type GBM strategy from the lab into a Phase 1 clinical trial, with a focus on how the therapy’s mechanism impacts patient outcomes
- Exploring the early-stage findings from this study and their implications for the future of GBM therapy, specifically through a patient-centric, immunotherapeutic approach
Wednesday 18th February 2026
Panel Discussion – Navigating Next-Generation GBM Immunotherapies & Delineating a Path to Clinical Success
11:00 am
- Diving into the scientific breakthroughs in GBM immunotherapies including oncolytic viruses, cell therapies and bispecific antibodies to overcome immunosuppression in the brain
- Navigating the biomarker validation process in order to identify reliable and predictive biomarkers accurately assess the effect of immunotherapies for GBM
- Advancing clinical endpoints for immunotherapies to overcome challenges involved with pseudo-progression
